Titan Pharmaceuticals, Inc. (TTNP) Research

Titan Pharmaceuticals, Inc. is a pharmaceutical company dedicated to creating treatments for chronic conditions, with its product development centered around ProNeura, a unique platform designed for extended drug release. Currently, the company markets the Probuphine implant in Canada and the European Union. This implant provides maintenance treatment for clinically stable individuals struggling with opioid use disorder. Beyond Probuphine, Titan Pharmaceuticals is advancing several pipeline candidates. Among these is the kappa opioid agonist peptide program (TP-2021), which utilizes the ProNeura technology to address chronic pruritus. Another key development is a nalmefene implant program, aimed at preventing opioid relapse in patients after detoxification from opioid use disorder. Furthermore, the company is exploring other applications for its ProNeura platform, including a single implant for HIV prevention and a contraceptive option for women and adolescent girls. Established in 1992, Titan Pharmaceuticals operates from its base in South San Francisco, California.

Market snapshot

Symbol
TTNP
Price
$2.34
Day change
-11.36%
Market cap
$5.8M
P/E ratio
13.82x
52-week range
2.33-15.15
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Can-Fite BioPharma Ltd. (CANF)
  • Clearmind Medicine Inc. (CMND)
  • CNS Pharmaceuticals, Inc. (CNSP)
  • Ensysce Biosciences, Inc. (ENSC)
  • Kazia Therapeutics Limited (KZIA)
  • Oragenics, Inc. (OGEN)
  • Qualigen Therapeutics, Inc. (QLGN)
  • Silo Pharma, Inc. (SILO)

Recent insider activity

  • Ben-Tzvi Avraham — D-Return (3313 shares) on 2025-10-01
  • Ben-Tzvi Avraham — D-Return (5000 shares) on 2025-10-01
  • Loh Gabriel — trade (0 shares) on 2025-03-27
  • Jye Chay Weei — trade (0 shares) on 2025-03-20
  • Mokhtar Firdauz — trade (0 shares) on 2024-04-02

Open Titan Pharmaceuticals, Inc. (TTNP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.